anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1423179 Pressurized shaving foam dispensers WILKINSON SWORD Ltd 14 May 1974 [16 May 1973] 23410/73 Headings C4X and C5D A shaving foam package comprises a pressurized dispenser equipped with a dispensing head and valve and contains therein a foamforming aqueous emulsion consisting essentially of (A) an aqueous concentrate containing (i) from 1À3-15% by weight, based on the weight of the concentrate, of one or more water-soluble or substantially water-soluble synthetic anioniccompatible surfactants; (ii) from 0À5 to 6À0% by weight, based on the weight of the concentrate, of one or more water-insoluble long-chain fatty alcohols; and (iii) from 2-12% by weight, based on the weight of the concentrate, of an anionic surfactant selected from alkali metal or alkanolamine soaps, i.e. salts of fatty acids containing from 10-22 carbon atoms, long-chain alkyl and alkaryl sulphates and ether sulphates, long-chain alkyl and alkaryl sulphonates, longchain N-acyl sarcosinates, and mixtures of two or more thereof, the anionic surfactant constituting component (iii) being of a different type from that constituting component (i) when the latter is itself anionic, the balance of the concentrate being water; and emulsified therewith (B) a liquefied propellant gas; the weight ratio of total surfactant i.e. components (i) and (iii) together, to long-chain fatty alcohol being from 1 : I to 20 : 1 and the weight ratio of total synthetic surfactant plus long-chain fatty alcohol, to soap, when the anionic surfactant is or contains soap, being in the range 0À5 : 1 to 4 : 1. "Long-chain" refers to groups of 12-18 carbon atoms and "long-chain alkaryl" refers to a benzene or naphthalene nucleus substituted by a C 5 -C 12  alkyl substituent. Component (i) may be a nonionic surfactant selected from ethylene oxide or propylene oxide adducts of long-chain fatty alcohols, acids and amides, ethylene oxide or propylene oxide adducts of polyol esters of long-chain fatty acids, ethylene oxide or propylene oxide adducts of long-chain alkyl phenols, polyoxyethylene adducts of polyoxypropylene glycol, long-chain fatty acid alkanolamides and polyol esters of long-chain fatty acids. The long-chain fatty alcohol may be myristyl alcohol. Components (iii) may be a lauryl sulphate, a lauryl ether sulphate, an octylphenyl sulphonate, a nonylphenyl sulphonate or sodium lauroyl sarcosinate.
Multiple genetic, environmental, and immunological variables cause neuropsychiatric disorders (NPDs). The induced inflammatory immune response is also connected to the severity and treatment outcomes of various NPDs. These reactions also significantly impact numerous brain functions such as GABAergic signaling and neurotransmitter synthesis through inflammatory cytokines and chemokines. Chalcones (1,3-diaryl-2-propen-1-ones) and their heterocyclic counterparts are flavonoids with various biological characteristics including anti-inflammatory activity. Several pure chalcones have been clinically authorized or studied in humans. Chalcones are favored for their diagnostic and therapeutic efficacy in neuroinflammation due to their tiny molecular size, easy manufacturing, and flexibility for changes to adjust lipophilicity ideal for BBB penetrability. These compounds reached an acceptable plasma concentration and were well-tolerated in clinical testing. As a result, they are attracting increasing attention from scientists. However, chalcones' therapeutic potential remains largely untapped. This paper is aimed at highlighting the causes of neuroinflammation, more potent chalcone congeners, their mechanisms of action, and relevant structure-activity relationships.
The highly secure method and system acquires, processes and produces health care (HC) data and service records from multiple local devices, notwithstanding different operating systems (OS) in such devices, and all accessed and controlled by a cloud computing network. Devices have memories, displays, keypads, cameras and microphones. The system operates on acquired data including image, keypad-text, audio, and speech-converted-to text data generated by respective devices. The method downloads commands to devices (notwithstanding different OS) which delete-acquired-data upon a request to save (upload) data to the cloud computing network. Further data security includes a disable-print-screen command prohibiting local storage of stored acquired data into local devices. The method and system also produces a customized surgical schedule by (a) obtaining the GPS location of a local device (b) filtering out the non-surgical appointments from the complete appointment schedule of the HC professional; and (c) displaying only surgical appointments.
PURPOSE: To selectively magnetize nonmagnetic particles and paramagnetic particles by preparing a water dispersion mixed with magnetic material particles coated with an inner layer and outer layer consisting of monomolecular layers of a specific water soluble, org. heteropolar surfactant. CONSTITUTION: The inner layer consisting of the monomolecular layer of the first water soluble, org. heteropolar surfactant having >=3 carbon atoms and having a functional group on one terminal and hydrophobic terminal forming a bond with the magnetic particles is formed on the particles of the magnetic material. Further, the surface of this inner layer is coated with the outer layer consisting of the monomolecular layer of the second water soluble, org. heteropolar surfactant having >=3 carbon atoms and having the hydrophobic terminal bonded with the hydrophobic terminal of the first surfactant and another functional group oriented outward toward the water. The reagent for magnetizing the nonmagnetic material is prepd. by dispersing the particles of the magnetic material having such inner layer and outer layer into the water.
PURPOSE: This study compared the predictive performance of the relative enhancement index (REI) derived from gadoxetic acid (GA)-enhanced MRI with that of the functional liver imaging score (FLIS) in estimating liver function among patients with chronic liver disease (CLD) or liver cirrhosis (LC) by validating them with the albumin-bilirubin (ALBI) grade.
MATERIALS AND METHODS: We retrospectively examined 166 patients (79 women, 87 men; 57.4 years) who were diagnosed with LC or CLD and underwent GA-enhanced MRI between August 2020 and September 2023. The enhancement ratio (ER) is calculated using the formula: ER = [hepatobiliary phase liver signal (SI HBP20)-precontrast liver signal (SI pre)]/SI pre. The REI is calculated using the formula: REI = Liver Volume (LV) × ER. FLIS was assigned from the sum of three HBP image features, each scored between 0 and 2: liver parenchymal enhancement, biliary contrast excretion, and portal vein sign. Receiver operating characteristic (ROC) curve analysis was performed to determine the optimal cutoff values of ER, REI, and FLIS in differentiating between ALBI grades. The area under the curve (AUC), accuracy, sensitivity, and specificity were calculated for REI and FLIS to distinguish the ALBI grades. Spearman's rank correlation was used to evaluate the ER, REI, and FLIS correlations between the ALBI grades. To evaluate inter-reader reliability for LV, ER, REI, and FLIS, intraclass correlation coefficient (ICC) was used.
RESULTS: ROC curve analysis showed that the optimal cutoff value of REI for predicting ALBI Grade 1 was 899-905 for readers 1 and 2 and 461-477 for ALBI Grade 3, respectively. REI performed best in predicting ALBI Grade 1, achieving an accuracy range of 94%-92.2%, sensitivity of 94.9%-94.1%, and specificity of 91.7%-87.5% for readers 1 and 2, respectively. All parameters showed high accuracy in distinguishing ALBI Grade 3 from other grades. However, REI outperformed the others, showing an accuracy range of 98.8%-97.6%, sensitivity of 94.4%-94.4%, and specificity of 99.3%-98% for readers 1 and 2, respectively. REI showed the best and very strong correlation with ALBI for both readers.
CONCLUSION: REI showed a very strong correlation with the ALBI grades for assessing liver function. It outperformed FLIS in predicting the ALBI grades, indicating its potential as a radiologic tool comparable to or better than FLIS in predicting liver function, especially given its dependence on liver volume.
Active sessions will last 1 hour of stimulation per day for 2 weeks. The following parameters will be used for electric stimulation: low frequency (20 Hz), low current intensity (2 mA), with a small pulse width of 25-170 microseconds.
Totally 5 municipalities (25 persons with dementia) will be included in the Control group. The municipalities in the control group will receive the same two hours lectures about dementia and NPS as the intervention group. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
Paliperidone causes a modest increase in the corrected QT (QTc) interval. The use of paliperidone should be avoided in combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. Paliperidone should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

Certain circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval.

The effects of paliperidone on the QT interval were evaluated in a double-blind, active-controlled (moxifloxacin 400 mg single dose), multicenter QT study in adults with schizophrenia and schizoaffective disorder, and in three placebo- and active-controlled 6-week, fixed-dose efficacy trials in adults with schizophrenia.

In the QT study (n = 141), the 8 mg dose of immediate-release oral paliperidone (n=50) showed a mean placebo-subtracted increase from baseline in QTcLD of 12.3 msec (90% CI: 8.9; 15.6) on day 8 at 1.5 hours post-dose. The mean steady-state peak plasma concentration for this 8 mg dose of paliperidone immediate-release was more than twice the exposure observed with the maximum recommended 12 mg dose of paliperidone (C max ss = 113 ng/mL and 45 ng/mL, respectively, when administered with a standard breakfast). In this same study, a 4 mg dose of the immediate-release oral formulation of paliperidone, for which C max ss = 35 ng/mL, showed an increased placebo-subtracted QTcLD of 6.8 msec (90% CI: 3.6; 10.1) on day 2 at 1.5 hours post-dose. None of the subjects had a change exceeding 60 msec or a QTcLD exceeding 500 msec at any time during this study. 

For the three fixed-dose efficacy studies in subjects with schizophrenia, electrocardiogram (ECG) measurements taken at various time points showed only one subject in the paliperidone 12 mg group had a change exceeding 60 msec at one time-point on Day 6 (increase of 62 msec).

No subject receiving paliperidone had a QTcLD exceeding 500 msec at any time in any of these three studies.
A controlled randomized study will be conducted to assess the effectiveness of the educational program before and after its implementation. An invitation to participate will be extended to physiotherapists interested in the training program. More than 64 physiotherapists will be randomly assigned to two equal groups. All participants will sign an informed consent form before the commencement of the study and will be informed about the study's content, duration, and their right to withdraw at any time. A structured educational program consisting of two parts will be developed, encompassing three core modules (Part A) on the management of chronic pain and three core modules (Part B) on communication skills and techniques. The modules in Part A of the educational program will focus on elucidating the neurophysiological mechanisms of pain, performing differential assessments based on chronic musculoskeletal pain phenotypes, and addressing and managing the factors contributing to patients' pain experiences and rehabilitation, with a particular emphasis on pain neuroscience education. The modules in Part B of the educational program will concentrate on the development of communication skills essential for effective interaction between patients and physiotherapists. The first group will complete all modules of the educational program, while the second group (control group) will only participate in the Part A education modules. The effectiveness of the program will be evaluated before and after its implementation by two independent examiners through the administration of an Objective Structured Clinical Examination (OSCE) and the use of reliable and valid questionnaires/scales. Upon completion of the program and its evaluation, participants in the control group will have the opportunity to complete the communication skills training as well.
A pair of TCPRF electrodes will be applied to the painful shoulder at six standardized sites for 2 minutes each (approximately a total of 15 minutes). It will be activated in the study group. In the study group device will be set at 80 V, every pulse will continue for 10 milliseconds and 5 pulses per second. TCPRF treatment is going to be applied for one session in both groups.
Thyroid cancer is a common neck malignancy and it mainly affects thyroid follicular cells or parafollicular cells. Thyroid cancer in various tumors in the body, the ratio can reach 1.2% to 2.3%. Thyroid cancer can be divided into differentiated thyroid cancer, squamous cell carcinoma, undifferentiated carcinoma, and medullary carcinoma, among which the incidence of differentiated thyroid carcinoma is more than 90%. At present, total thyroidectomy or subtotal thyroidectomy is the main method for the treatment of thyroid cancer patients, but some thyroid cancer may still have residual thyroid tissue after operation. Therefore, in the treatment of differentiated thyroid cancer, iodine 131 is mainly used. Treatment, because iodine 131 can emit high-energy beta rays, destroying the residual tissue of thyroid cancer, to achieve good therapeutic purposes. However, due to the presence of sodium iodine symporter in salivary glands and thyroid, it is inevitable that certain salivary glands will be damaged in the treatment of iodine 131, and patients will have dry mouth symptoms. Some patients with nausea 131 will also experience nausea and vomiting. Gastrointestinal reaction. Iodine 131 treatment is divided into two steps: 1 removal of residual thyroid tissue; 2 removal of cancer lesions and metastases. The curative effect of 131I depends on the lesion's uptake of iodine-131, which requires an increase in serum TSH levels. All patients in this study had stopped taking thyroid hormone for 3 to 4 weeks before iodine-131 treatment. The TSH level is greater than 30 mU/L. At this time, the patient is in hypothyroidism. People with hypothyroidism experience dry mouth, dry skin, constipation, pain, cold, poor memory, depression, and weight gain. Many studies have pointed out that some cancer treatments, such as chemotherapy and radiotherapy, also have an impact on the microbial flora. However, studies on the relationship between microecology, hypothyroidism and iodine-131 treatment, probiotics in the prevention of hypothyroidism and iodine-131 treatment The link between the effects of side effects remains unclear. Therefore, the team will conduct a correlation study between microbes and hypothyroidism, iodine-131 treatment.
Family caregivers will receive three sessions of the PISCES intervention in person. The agenda for the first face to face visit for caregivers (suggested timeline 5-7 days after hospice admission) includes an explanation of the purpose of the visit/call. During the first session, the interventionist works on steps one and two of the ADAPT model, namely "Attitude" and "Defining the Problem and Setting Realistic Goals." During the second visit (suggested timeline 11-13 days after hospice admission) the interventionist covers steps three and four of the ADAPT model. Step three encourages caregivers in being creative and generating alternative solutions. Step four focuses on predicting the consequences and developing a solution plan. The third visit (suggested timeline 16-18 days after hospice admission) focuses on step five, namely trying out the solution plan and determining if it works.
NEW MATERIAL:beta-Glucans produced by culturing a microorganism belonging to Macrophomopsis genus and having a structure containing the following form of bonding. (A) All the D-glucopyranose residues of the main chain are beta-1,3 bond. (B) Branching at C-2 position and/or C-6 position of the D-glucopyranose residue of the main chain. (C) D-glucopyranose residues of side chains contain no beta-1,4 bond. USE:Useful as a thickening agent, an emulsifier, a stabilizer and a humectant in various fields such as food fields and cosmetic field. PREPARATION:A microorganism belonging to Macrophomopsis genus such as Macrophomopsis KAB 55 strain (FERM P-9366) is cultured at pH 5.0-8.0 and 20-35 deg.C for 3-7 days.
Infants dependent on parenteral nutrition for greater than 1 year who develop parenteral nutrition associated cholestasis will universally face mortality unless they receive a timely liver and/or small bowel transplant. Although transplant survival has improved in recent years, survival is not guaranteed, and transplant care remains costly. Alternative nutritional and pharmacological strategies are imperative to improve the clinical outcomes of infants with intestinal failure and parenteral nutrition associated cholestasis. In both animal and human studies, intravenous fish oil, a lipid emulsion rich in omega-3 fatty acids and Vitamin E, and lacking phytosterols, has been shown to ameliorate parenteral nutrition associated cholestasis and improve morbidity and mortality. The purpose of this pilot study is to investigate if Omegaven, a commercially available intravenous fish oil, at 1 g/kg/d, will safely reverse liver disease in 80 subjects with parenteral nutrition associated cholestasis. Subjects can initially receive a maximum of 6 months (24 weeks) of intravenous fish oil. If the subject re-develops liver disease and still satisfies inclusion/exclusion criteria, the intervention can be restarted. Study subjects will be compared to a historical cohort of children with Short Bowel Syndrome and parenteral nutrition associated cholestasis who have been receiving standard intravenous soybean oil for \> 60 days. The fish oil cohort will be followed for a total of 5 years to determine if transplant-free mortality is reduced.
Naltrexone hydrochloride (HCl)/bupropion hydrochloride (HCl) placebo-matching tablet, orally, 1 tablet in the AM, daily, during Week 1, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 1 tablet in the AM and 1 in the PM, during Week 2, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 1 in the PM, during Week 3, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 2 in the PM, in Week 4 through Week 49. Participants must be re-titrated if off treatment for ≥1 week (≥7 days).
Participants randomized to the digital control condition, DISC-CON, will be asked to download and use the BUILD study application. They will have access to the app throughout the 2 week study.
BACKGROUND: Preterm birth (PTB) contributes to nearly 11% of all deliveries in the world. The majority of spontaneous preterm birth (sPTB) remains unexplained. Risk factors include abnormal body mass index (BMI), short cervical length, comorbidities and many more. However, there is limited study on the association between body mass index, cervical length and preterm birth in Malaysia among low-risk women. Hence, we aim to examine the relationship between body mass index, cervical length and the risk of spontaneous preterm birth.
METHOD: In this prospective cohort study, pregnant women between 16 and 24 weeks who fulfilled the criteria were recruited. Women with history of preterm birth were excluded. Demographic and clinical data (age, BMI, ethnicity, education level and parity) were obtained. Cervical length was measured using transvaginal scan. Patients were then followed up till delivery to determine their delivery gestation and outcome of delivery.
RESULTS: Out of 153 women who participated in this study, 146 women had cervical length of more than 30 mm, six had cervical length between 25 mm and 30 mm and one had cervical length of 24 mm. There were nine (9) cases of sPTB, with all of them being late preterm with normal midtrimester cervical length. Almost half of them (44%) were overweight/obese. A significant association was found between age, cervical length, and parity compared to BMI. Nevertheless, no significant association was seen between the BMI and risk of sPTB.
CONCLUSION: This study demonstrates a higher BMI is associated with longer cervical length, but it is not necessarily protective against sPTB. Hence, we concluded there is a limited role in cervical length screening among low-risk women regardless of their BMI in predicting sPTB.
The invention relates to a preparation for the prophylaxis of restenosis. Sufficient active ingredient concentration in the relevant areas of the blood vessel walls cannot be achieved with preparations for the prophylaxis of restenosis known in prior art due to the fact that higher doses cause side effects. According to the invention, at least one lipophilic, anti-hyperplastic active ingredient having a distribution coefficient between butanol and water of >/= 0.5 is added to a preparation. A sufficient amount of the lipophilic active ingredient is rapidly absorbed in the blood vessel wall. The preparation can be liquid or distributed by capillarity and can contain a contrast medium so that passage of active ingredients to the blood vessels occurs without further complications as is normally required in contrast images. The preparation can also be applied on a catheter.
PURPOSE: To obtain an anti-hypertensive agent effective for light hypertension, containing vitamin D and the like and a polymeric substance such as a polysaccharide having the ability to bind to sodium. CONSTITUTION: This anti-hypertensive agent contains a polymeric substance such as a polysaccharide having the ability to bind to sodium (pref. alginate, esp. pref. potassium alginate) and a vitamin D and the like (derivative/analogue). The above polymeric substance may be another type of polysaccharide such as pectin, xanthan, galactomannan, or glucomannan, being used either in genuine form or in the form of being included into various dietary fibers. The vitamin D acts synergistically with the blood pressure depression induced by the above polymeric substance in the case of patients with light hypertension, its amount to be used being 0.02μg based on a capsule containing 0.5g of potassium alginate.